Physician profile
Bailey K Trimble
NPI 1891487104
$6,135.45
in general payments reported to CMS, 2019-2025
50 companies · $3,223 in 2025
The $3,223 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $163 · 2024: $2,749 · 2025: $3,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,529 · Education: $607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,528.93 |
| Education | $606.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $513.21 | 2024-2025 | Rybrevant, Erleada, Darzalex |
| Daiichi Sankyo INC. | $493.68 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Pfizer INC. | $483.94 | 2024-2025 | |
| Astellas Pharma US INC | $400.17 | 2024-2025 | Xtandi |
| Astrazeneca Pharmaceuticals LP | $337.88 | 2024-2025 | Tagrisso, Enhertu, Lynparza |
| Novartis Pharmaceuticals Corporation | $319.21 | 2024-2025 | |
| Celgene Corporation | $244.42 | 2024-2025 | Reblozyl, Pomalyst, Opdivo |
| Seagen INC. | $226.38 | 2023-2025 | Padcev, Adcetris |
| Bayer Healthcare Pharmaceuticals INC. | $212.52 | 2024-2025 | |
| Abbvie INC. | $195.51 | 2024-2025 | |
| Beone Medicines USA, INC. | $176.09 | 2025 | Brukinsa, Tevimbra |
| Exelixis INC. | $151.69 | 2025 | Cabometyx |
| Genzyme Corporation | $148.21 | 2024-2025 | |
| Incyte Corporation | $143.79 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Merck Sharp & Dohme LLC | $130.52 | 2024-2025 | Keytruda, Reblozyl, Lynparza |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $125.01 | 2024 | Opdivo |
| Jazz Pharmaceuticals INC. | $124.82 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.27 | 2024-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Adc Therapeutics America, INC. | $106.60 | 2024-2025 | |
| Sobi, INC | $102.48 | 2024-2025 | |
| Array Biopharma INC | $95.38 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Eisai INC. | $90.96 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $85.86 | 2024-2025 | Onivyde |
| Glaxosmithkline, LLC. | $82.50 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Regeneron Healthcare Solutions, INC. | $73.69 | 2023-2025 | Libtayo, Lynozyfic |
| Pharmaessentia USA Corporation | $70.45 | 2024-2025 | Besremi |
| Coherus Oncology, INC. | $66.68 | 2024-2025 | Loqtorzi |
| Karyopharm Therapeutics INC. | $65.62 | 2024-2025 | Xpovio |
| Pharmacosmos Therapeutics INC. | $51.47 | 2025 | Monoferric |
| Menarini Silicon Biosystems, INC. | $51.20 | 2025 | |
| Lilly USA, LLC | $50.33 | 2023-2024 | Jaypirca, Verzenio, Retevmo |
| Tersera Therapeutics LLC | $48.00 | 2024 | Zoladex |
| Servier Pharmaceuticals LLC | $47.98 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $47.88 | 2025 | Alymsys, Pemrydi Rtu |
| Stemline Therapeutics INC. | $43.94 | 2025 | Orserdu |
| Geron Corporation | $43.62 | 2025 | Rytelo |
| Alexion Pharmaceuticals, INC. | $42.49 | 2024 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.76 | 2025 | |
| Caris Mpi, INC. | $36.76 | 2025 | Mi Cancer Seek |
| Kyowa Kirin, INC. | $27.01 | 2025 | |
| Novocure INC. | $25.96 | 2024 | Optune Lua (Novottf-200t) |
| Genentech USA, INC. | $25.22 | 2024 | Venclexta |
| Sun Pharmaceutical Industries INC. | $23.80 | 2024 | |
| Emd Serono, INC. | $22.75 | 2025 | |
| Aveo Pharmaceuticals, INC. | $22.53 | 2025 | |
| Fennec Pharmaceuticals, INC. | $20.45 | 2024 | Pedmark |
| Acrotech Biopharma INC. | $20.41 | 2024 | Ryzneuta |
| Puma Biotechnology, INC. | $19.24 | 2025 | |
| Accord Healthcare, INC. | $17.94 | 2024 | |
| Sumitomo Pharma America, INC. | $15.17 | 2023 | Orgovyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bailey Trimble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.